← back to search

Samir V. Parikh

RWTH Aachen University · US
Area of research
Nephrology · Rheumatology
Research interest
Research interests include Renal Diseases and Glomerulopathies, Systemic Lupus Erythematosus Research, Chronic Kidney Disease and Diabetes, and Renal and related cancers.
h-index
35
citations
5,519
works
153
NIH funding
primary concept
Medicine
email

Recent publications

Effect of Long-Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies.
2025cited by 2position: contributordoi
Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.
2024cited by 70position: contributordoi
The chromatin landscape of healthy and injured cell types in the human kidney
Nature Communications 2024cited by 38position: middledoi
Clinical Evaluation and Management of Thrombotic Microangiopathy.
2024cited by 28position: contributordoi
Plasma proteomics of acute tubular injury
Nature Communications 2024cited by 13position: middledoi
Inhibition of complement factor C5a or C5aR for cholesterol crystal embolism–related vascular thrombosis with microvascular injury and its consequences
Kidney International 2024cited by 12position: middledoi
An atlas of healthy and injured cell states and niches in the human kidney
Nature 2023cited by 624position: middledoi
Safety and Efficacy of <scp>Long‐Term</scp> Voclosporin Treatment for Lupus Nephritis in the Phase 3 <scp>AURORA</scp> 2 Clinical Trial
Arthritis & Rheumatology 2023cited by 101position: middledoi
A reference tissue atlas for the human kidney
Science Advances 2022cited by 167position: middledoi
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
American Journal of Nephrology 2022cited by 59position: middledoi
Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis
Arthritis Care & Research 2022cited by 44position: middledoi
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
American Journal of Nephrology 2022cited by 22position: middledoi
Genomic Study on Blood Culture Isolates From Patients With Staphylococcus Infection-associated Glomerulonephritis
Kidney International Reports 2022cited by 2position: middledoi
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
The Lancet 2021cited by 568position: middledoi
Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
American Journal of Kidney Diseases 2021cited by 19position: middledoi
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
Arthritis & Rheumatology 2020cited by 203position: middledoi
A multimodal and integrated approach to interrogate human kidney biopsies with rigor and reproducibility: guidelines from the Kidney Precision Medicine Project
Physiological Genomics 2020cited by 83position: middledoi
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
New England Journal of Medicine 2019cited by 584position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Amit Saxena · NYU Langone Health4 papers (2022–2025)Laura Lisk · Aurinia (Canada)3 papers (2021–2023)Ellen M. Ginzler · SUNY Downstate Health Sciences University3 papers (2021–2023)Y K Onno Teng · Kunming University of Science and Technology3 papers (2021–2023)Keisha L. Gibson · University of North Carolina at Chapel Hill3 papers (2021–2023)Robert B. Huizinga · Geomechanica (Canada)3 papers (2021–2023)Simrat Randhawa · Aurinia (Canada)3 papers (2021–2023)Cristina Arriens · Karolinska Institutet3 papers (2021–2023)Dawn J. Caster · University of Louisville3 papers (2021–2023) · 2 papers (2022–2022)Craig B. Langman · Northwestern University2 papers (2022–2022)Bradley P. Dixon · University of Colorado Denver2 papers (2022–2022)Steven D. Podos · University of Notre Dame2 papers (2022–2022)Tatsuya Atsumi · Hokkaido University2 papers (2022–2023)Matthew C. Pickering · Imperial College Healthcare NHS Trust2 papers (2022–2022)H. Terence Cook · Imperial College Healthcare NHS Trust2 papers (2022–2022)Neil Solomons · University of California San Diego2 papers (2021–2022)Gerald B. Appel · NewYork–Presbyterian Hospital2 papers (2022–2022) · 2 papers (2024–2025)Vanessa Birardi · Aurinia (Canada)2 papers (2024–2025)